Induction of CD8+ T-Cell Responses Against Novel Glioma–Associated Antigen Peptides and Clinical Activity by Vaccinations With α-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma
"Two patients (patients 1 and 20) experienced objective clinical tumor regressions (response rate, 9%).
Nine patients (41%; four and five with GBM and AG, respectively) are progression free for at least 12 months."
very little about ict 107 design is different so this bodes ill for the future phase ii multi arm study considering the unusually high antigen frequency in the single arm pi study
Can't agree with your extrapolation to the ICT-107 study from this. But PFS achieved here of twelve months for approx a third of the GMB patients in the study (4 of the 13 enrolled with that diagnosis) are actually good results. In a recent Avastin GBM trial, PFS in the placebo arm was on average about 7 months. It would be very good news if you could make a fair comparison to ICT-107 based on just these data. You can't. For several reasons.
The antigens were used in this vaccine differ from ICT-107 and the DC loading and cultivating tech was different, and additionally there was an important immunomodulating adjuvant involved (poly-ICLC).
So you have no basis at all for comparison good or bad, really.